Comparison of survival after propensity score matching and neoadjuvant chemotherapy prognostic factors The adjuvant XELOX group showed a trend toward better survival compared to the perioperative SOX group (95% CI = 0.388–1.205, P = 0.18).
FdU treatment alone showed a trend toward enrichment for subsets of macrophages that were negative in expression of CD206 (Mac_II) and CD80 + CD86 + (Mac_VI) ( P = 0.18, P = 0.046).
IC visibility was used as a simple parameter to identify anterior or posterior pump rotation in the LAT X‐rays, and showed a trend of higher proportion of patients with a visible IC (57.1%) in those who suffered from HS versus no HS (26.7%, p = 0.18).
Landmark analysis at 12 weeks also showed a trend toward better PFS in patients with mild irAEs, than in those with severe irAEs or without irAEs (HR 0.63, 95% CI: 0.32–1.25, p = 0.18).
5.1 months; HR 0.53, p < 0.0001) and showed a trend toward improved OS (20.7 vs. 16.8 months, p = 0.18).
The pooled estimate showed a trend toward fewer IH with mesh (OR 0.09 [0.00–3.13], p = 0.18), though this was not statistically significant.
Comparing the spatially averaged temporal standard deviation of the residual error signal, whole-brain values for DORK+dPLACE+DMA were significantly reduced compared to those obtained with baseline post-processing (p < 0.05); and showed a trend toward reduction when compared to use of sPLACE (p = 0.18).
Samples with the IKZF1 plus profile showed a trend of imatinib resistance ( P = .18; Dunn test; Figure 3 B).
Though not statistically significant, GDM patients showed a trend to have a higher mean GWG than controls (1.2 vs 0.7 kg, P = 0.18).
Patients with higher than median serum sCD163 levels showed a trend for more unfavorable overall survival ( p = 0.18, HR 1.4, 95% CI 16.7–43.2 for patients with values below median and 61.1–160.8 for patients with values above median).
those in the placebo group, whereas HBV-positive patients showed a trend in favor of sorafenib rather than placebo for TTP (HR: 0.74; 95% CI 0.48–1.14; P = 0.18) and OS (HR: 0.74; 95% CI 0.544–1.03; P = 0.08) [ 21 ].
≤ 3 mm) was significantly associated with lower survival ( P = 0.03), whereas DFS showed a trend ( P = 0.18).
EtOH-EVs) while UNC showed a trend toward a reversal (p=0.18).
Age showed a trend to be higher in the IETAVI group: 81 (78–82) vs. 72 (70–79) years (p = 0.18).
The American Society of Parenteral and Enteral Nutrition (ASPEN) recommends avoidance of IEN in high-risk patients based on 2 small RCTs which showed a trend towards higher mortality with IEN (13.9% IEN vs 7.4% CEN; p = 0.18) and increased risk of ventilator association pneumonia with IEN (49.3% IEN vs 30.9% CEN, p=0.02) [ 1 , 7 , 8 ].
HBV-positive patients showed a trend in favor of sorafenib rather than placebo for TTP (HR 0.74 CI 95% 0.48–1.14 p = 0.18) and OS (HR 0.74 CI 95% 0.544-1.03 p = 0.08) ( Figure 1C and Figure 1D ).
The G allele of rs322139 showed a trend of association with decreased risk for thromboembolism in UIC (OR = 0.70, p = 0.18, N = 198), adjusting for age, gender, haemoglobin genotypes, hydroxyurea therapy, recent blood transfusion and population stratification.
Finally, the trajectory of GLS of patients with and without cardiotoxicity showed a trend for a higher GLS increase per month in patients with cardiotoxicity compared to patients without cardiotoxicity (median 0.65%-points versus 0.20%-points, p = 0.181) (Fig. 4 ).
Sequential ZOL treatment after TPT showed a trend to increase the lumbar T-score from a mean ± SD T-score of −2.37 ± 1.33 after TPT to −2.11 ± 1.34 after ZOL treatment (Fig. 2a , p = 0.181).
Vinflunine showed a trend towards improved OS; median OS in vinflunine vs BSC group was 16.7 months vs 13.2 months respectively (HR-0.736; 95% CI, 0.44–1.24, p = 0.182); objective responses were achieved in 21% patients in vinflunine group vs 7% in BSC group respectively and vinflunine had an acceptable safety profile.
The increase in CA's approval rates showed a trend but was not statistically significant ( P = .094), NY shows the strongest and most significant trend ( P = .002), while WA shows a positive trend that was not statistically significant ( P = .182).
The subtotal glossectomy subgroup showed a trend toward improvement that did not reach statistical significance (median, 6.5 vs 6.0; P = 0.182; r = 0.231), and the total glossectomy subgroup (n=9) was too small for meaningful statistical comparison.
The other three feeding groups, 6FN, LNB and GNB, showed a trend ( p = 0.182, 0.164 and 0.171, respectively) toward increased expression levels of that TLR gene ( Figure 9b , c, d).
Firstly, compared to CPT1A low , DNMT3A and DNMT3B showed significantly higher expression in CPT1A high group ( P = 0.001 and P < 0.001, respectively), and DNMT1 also showed a trend of higher expression ( P = 0.182) ( Fig. 5 A).
In the intestine ( Figure 6 ), the treatment in the IUGR-VEGF and IUGR-IGF groups showed a trend to increase both the number of crypts/mm 2 ( p = 0.183) and the number of villi/mm 2 when compared with the IUGR-CON group ( p = 0.089); however, both the IUGR-VEGF and IUGR-IGF groups showed a significantly shorter villous length and a trend toward a lower crypt depth than in the IUGR-CON group ( p = 0.045 and p = 0.147, respectively). 4.